The U.S. Food and Drug Administration has issued a recall for three specific lots of dabigatran etexilate, a common blood thinner medication. The products were distributed nationwide by Major Pharmaceuticals and sold in various capsule strengths. Stability testing revealed that the medication failed to meet dissolution requirements, meaning it cannot maintain its intended quality over the standard 12-month window.
This recall is classified as Class III. According to the FDA, this indicates that the product is not likely to cause adverse health consequences. No evidence of contamination or incorrect active ingredients exists, but the agency requires the removal of these specific lots from circulation to ensure product standards are met.
Consumers should inspect their current medication supplies to identify any affected packs. You can verify your medicine by checking the NDC number, lot code, and expiration date against the official manufacturer records. If you have any of the impacted items, take them back to your pharmacy to request a refund or a replacement.
For anyone needing further clarification or specific guidance, the FDA provides a direct contact line at 1-888-463-6332. Please monitor your prescription supply and contact your healthcare provider if you have concerns regarding your treatment plan during this transition.